The Pfizer Centers for Therapeutic Innovation (CTI) program is a collaboration between Pfizer, Sanford Burnham Medical Research Institute (SBMRI), and UC San Diego investigators to develop protein therapeutics (e.g., monoclonal antibodies, antibody variants, recombinant proteins, Fc-fusions, pegylated proteins, antibody and protein conjugates, bispecific antibodies and peptides) and take them through successful proof-of-mechanism studies in humans.
Please check the CTRI Announcements page for funding opportunities.
When proposals are sought, the following guidelines apply:
All researchers, clinicians, and postdoctoral fellows may apply. Pre-proposals are selected by a Joint Steering Committee (JSC) with representation from UC San Diego, SBMRI, and Pfizer CTI. Authors of selected Pre-proposals will be invited to submit full Proposals to be written in collaboration with Pfizer scientists. The JSC will evaluate and select the projects, determine their funding, and monitor their progress.
The CTI focuses on the following disease topics:
• Autoimmunity (Systemic Lupus Erythematosus, Lupus Nephritis)
• Renal Disease (Kidney Injury/Lupus Glomerulonephritis, IgA Nephropathy)
• Cardiovascular (Congestive Heart Failure, Post-Myocardial Infarction, Acute Coronary Syndrome
Key criteria for project selection and funding will include:
• Strength of data supporting validation of the target
• Relevance to human disease
• Ability of target to be treated with drug(s) based on protein therapeutics
• Scientific assets (including potential lead candidate drugs)
• Feasibility of scientific project
• Clear path forward to proof-of-mechanism studies in humans
Note: Proposals that impact orphan or rare diseases are encouraged.